FDA calendar · November 2022 · built from SEC filings

PDUFA dates November 2022: FDA calendar and catalysts.

Updated Snapshot 20261116T222116ZBuilt

0 PDUFA dates fell in November 2022. The FDA calendar also recorded 25 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

PDUFA dates in November 2022

No PDUFA dates are disclosed for this period as of November 16, 2026.

Download: CSV · JSON · iCal (next 30 days, CC BY 4.0) · Calendar API · All months

November 2022: other FDA decisions and filings

DateDrugCompanyEventIndicationStatusSource
Nov 2022Month disclosedreproxalapALDXNDA/BLA submission—CompletedSEC 8-K Exhibit 99.1
Nov 2022Month disclosedneopeptides (EVX-01)EVAXNDA/BLA submissionwith metastatic melanomaCompletedSEC Form 10-K
Nov 2022Month disclosedTZIELD® (teplizumab)MGNXFDA approval—ApprovedSEC Form 10-K
Nov 2022Month disclosedmirvetuximabPMVPFDA approval—ApprovedSEC 8-K Exhibit 99.1
November 4, 2022Rybrevant (amivantamab-vmjw)JNJLabel expansion—ApprovedopenFDA Drugs@FDA
November 8, 2022Libtayo (cemiplimab-rwlc)REGNLabel expansion—ApprovedopenFDA Drugs@FDA
November 9, 2022Elfabrio (pegunigalsidase alfa)PLXNDA/BLA submission—CompletedSEC Form 10-Q
November 10, 2022Imfinzi® (durvalumab)AZNLabel expansion—ApprovedopenFDA Drugs@FDA
November 10, 2022Imjudo (tremelimumab-actl)AZNFDA approval—ApprovedopenFDA Drugs@FDA
November 16, 2022Rezvoglar (insulin glargine-aglr)LLYFDA approval—ApprovedopenFDA Drugs@FDA
November 17, 2022Trulicity (dulaglutide)LLYLabel expansion—ApprovedopenFDA Drugs@FDA
November 22, 2022Piqray (alpelisib)NVSLabel expansion—ApprovedopenFDA Drugs@FDA
November 23, 2022—EVAXFDA approval—ApprovedSEC Form 10-K
November 28, 2022Udenyca (pegfilgrastim-cbqv)CHRSLabel expansion—ApprovedopenFDA Drugs@FDA
November 30, 2022Brexafemme (ibrexafungerp)GSKLabel expansion—ApprovedopenFDA Drugs@FDA

November 2022: dated readouts

DateDrugCompanyEventIndicationStatusSource
Nov 2022Month disclosedVIITALABEOTopline readout—PositiveSEC Form 10-K
Nov 2022Month disclosedCOMP360CMPSTopline readout—PositiveSEC Form 10-K
Nov 2022Month disclosedWAKIX® (pitolisant)HRMYTopline readout—PositiveSEC Form 10-K
Nov 2022Month disclosedTAVALISSE (fostamatinib)RIGLTopline readout—Missed primary endpointSEC Form 10-Q

November 2022: trial starts and primary completions

DateDrugCompanyEventIndicationStatusSource
Nov 2022Month disclosedzipalertinib (CLN-081)CGEMTrial start—CompletedSEC Form 10-K
Nov 2022Month discloseditolizumab (EQ001)EQTrial startmoderate to severe alopecia areata, or AA, in Australia and New ZealandCompletedSEC Form 10-Q
Nov 2022Month disclosedsevasemten (EDG-5506)EWTXTrial start—CompletedSEC Form 10-K
Nov 2022Month disclosedJAKAFI (ruxolitinib)INCYTrial start—CompletedSEC Form 10-Q
Nov 2022Month disclosedsuvecaltamide (JZP385)JAZZTrial startParkinson's disease tremorCompletedSEC Form 10-K
Nov 2022Month disclosedrepibresib (VYN201)YARWTrial startNSV in November 2022CompletedSEC Form 10-Q

Questions

What PDUFA dates are in November 2022?

0 PDUFA dates fell in November 2022. The FDA calendar also recorded 25 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

Can these dates change?

Yes. The FDA can extend a review by three months after a major amendment, and it sometimes acts before the goal date. Each row links the filing the date came from.

Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.